GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
A critical defect in type 2 diabetes is impaired insulin-stimulated glucose transport and metabolism in muscle and adipocytes. To understand the metabolic adaptations this elicits, we generated mice with targeted disruption of the GLUT4 glucose transporter in both adipocytes and muscle (AMG4KO). In contrast to total body GLUT4-null mice, AMG4KO mice exhibit normal growth, development, adipose mass, and longevity. They develop fasting hyperglycemia and glucose intolerance and are at risk for greater insulin resistance than mice lacking GLUT4 in only one tissue. Hyperinsulinemic-euglycemic clamp studies showed a 75% decrease in glucose infusion rate and markedly reduced 2-deoxyglucose uptake into skeletal muscle (85-90%) and white adipose tissue (65%). However, AMG4KO mice adapt by preferentially utilizing lipid fuels, as evidenced by a lower respiratory quotient and increased clearance of lipids from serum after oral lipid gavage. While insulin action on hepatic glucose production and gluconeogenic enzymes is impaired, hepatic glucokinase expression, incorporation of 14C-glucose into lipids, and hepatic VLDL-triglyceride release are increased. The lipogenic activity may be mediated by increased hepatic expression of SREBP-1c and acetyl-CoA carboxylase. Thus, inter-tissue communication results in adaptations to impaired glucose transport in muscle and adipocytes that involve increased hepatic glucose uptake and lipid synthesis, while muscle adapts by preferentially utilizing lipid fuels. Genetic determinants limiting this "metabolic flexibility" may contribute to insulin resistance and type 2 diabetes in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197 · cited 1×
“Recent data showing defective expression of genes involved in mitochondrial oxidative phosphorylation in humans with insulin resistance and type 2 diabetes (28, 29) support this notion.”
BackgroundSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053 · cited 1×
“Skeletal muscle, on the other hand, has a great capacity to transition between oxidation of carbohydrate and lipid fuels in response to hormonal, mainly insulin and possibly leptin (6), and substrate signals (7).”
BackgroundSelf-citationPatti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1032913100 · Cited by 1,952
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
Self-citationZisman, A., Peroni, O. D., Abel, E. D., Michael, M. D., Mauvais-Jarvis, F., Lowell, B. B., Wojtaszewski, J. F. P., Hirshman, M. F., Virkamaki, A., Goodyear, L. J., et al. (2000) · Nature Medicine · doi:10.1038/78693 · Cited by 743 · cited 2×
“Thus, to understand whether the downregulation of GLUT4 expression selectively in adipocytes in obesity or type 2 diabetes could contribute to the pathogenesis of insulin resistance and also to determine the importance of impaired glucose transport in muscle, we previously used Cre-LoxP gene targeting to knock out GLU…”
BackgroundMethodSelf-citationDiabetes mellitus and genetically programmed defects in β-cell function
Bell, G. I., & Polonsky, K. S. (2001) · Nature · doi:10.1038/414788a · Cited by 475 · cited 1×
“Introduction Type 2 diabetes is characterized by insulin resistance in muscle, liver, and adipocytes and impaired pancreatic β cell function (1).”
BackgroundAarsland, A., Chinkes, D., & Wolfe, R. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119005 · Cited by 212
Research works printed but not linked: 27
- 10.1038/3018 · DOI
- 10.1146/annurev.physiol.65.092101.142540 · DOI · Paper page
- 10.1074/jbc.R300019200 · DOI · Paper page
- 10.2337/diabetes.49.5.677 · DOI · Paper page
- 10.1038/35055575 · DOI · Paper page
- 10.1016/0169-328X(95)00306-D · DOI
- 10.1172/JCI116392 · DOI
- 10.1038/377151a0 · DOI · Paper page
- 10.1038/nm1097-1096 · DOI · Paper page
- 10.1016/S0169-328X(02)00487-4 · DOI
- 10.1172/JCI119711 · DOI · Paper page
- 10.2337/diabetes.48.10.2022 · DOI · Paper page
- 10.1126/science.1084073 · DOI · Paper page
- 10.2337/diabetes.49.2.272 · DOI · Paper page
- 10.2337/diabetes.50.6.1351 · DOI · Paper page
- 10.2337/diabetes.53.8.2042 · DOI · Paper page
- 10.1042/BJ20020430 · DOI · Paper page
- Ruderman, 1968, J. Lipid Res., 9, 613, 10.1016/S0022-2275(20)42708-7 · DOI
- Gibbons, 1992, Biochem. J., 287, 749, 10.1042/bj2870749 · DOI
- 10.1172/JCI7605 · DOI · Paper page
- 10.1016/S1097-2765(00)80155-0 · DOI · Paper page
- 10.1038/oby.2000.47 · DOI · Paper page
- 10.1172/JCI114636 · DOI · Paper page
- 10.1172/JCI1594 · DOI · Paper page
- Li, 1996, J. Lipid Res., 37, 210, 10.1016/S0022-2275(20)37649-5 · DOI · Paper page
- 10.1074/jbc.M207198200 · DOI · Paper page
- Minokoshi, 1986, Am. J. Physiol., 251, R1005
Cited by
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., & Kahn, B. B. (2005) · Nature · doi:10.1038/nature03711 · Cited by 2,086
Self-citationThe SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328
Ristow, M., & Zarse, K. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.03.014 · Cited by 789
Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes
Birkenfeld, A. L., & Shulman, G. I. (2014) · Hepatology · doi:10.1002/hep.26672 · Cited by 738
Extending life span by increasing oxidative stress
Ristow, M., & Schmeisser, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.010 · Cited by 722
Metadata
- Authors
- Kotani, K., Peroni, O. D., Minokoshi, Y., Boss, O., & Kahn, B. B.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-12-01
- Volume
- 114
- Issue
- 11
- Pages
- 1666-1675
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2004889053
- Cited by
- 139
- References
- 11
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. https://app.cochat.ai/papers/10.1172/jci200421341
- The paper
- Kotani, K., Peroni, O. D., Minokoshi, Y., Boss, O., & Kahn, B. B. (2004). GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. Journal of Clinical Investigation. https://doi.org/10.1172/jci200421341
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.